0VY.F I-MAB SPONS.ADS/1 -0001
- Market cap
- EUR 88.2M
- P/E
- -
- P/B
- 0.49x
- ROE
- -20.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0VY.F undervalued?
Graham numberThe Graham number of I-MAB SPONS.ADS/1 -0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
I-MAB SPONS.ADS/1 -0001 fundamental analysis
No fundamental analysis for I-MAB SPONS.ADS/1 -0001 yet.
I-MAB SPONS.ADS/1 -0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestina…
Full company profileI-MAB SPONS.ADS/1 -0001 financial statements
I-MAB SPONS.ADS/1 -0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 13.8M | -1.55M | 632K | 0.00 | 0.00 |
| Gross Profit | 6.53M | -36.1M | 3.90M | - | - |
| Operating Income | -323M | -53.1M | -49.0M | -51.4M | -94.3M |
| EBITDA | - | -51.7M | -47.9M | -50.4M | -93.4M |
| Net Income | -366M | -371M | -208M | -22.2M | -46.3M |
| EPS | -1.99 | -1.94 | -1.12 | -0.12 | -0.17 |
| Balance Sheet | |||||
| Total Assets | 879M | 590M | 369M | 213M | 261M |
| Total Liabilities | 163M | 169M | 126M | 11.5M | 29.6M |
| Shareholders' Equity | 715M | 422M | 243M | 201M | 231M |
| Cash & Short-term Investments | 553M | 466M | 292M | 68.3M | 211M |
| Cash Flow | |||||
| Operating Cash Flow | -153M | -49.6M | -72.7M | -52.7M | -20.6M |
| Capital Expenditure | 4.70M | 2.09M | 164K | 48.0K | 7.00K |
| Free Cash Flow | -157M | -51.7M | -72.9M | -52.7M | -20.6M |
| Ratios | |||||
| ROE | -51.1% | -88.0% | -85.6% | -11.1% | -20.0% |
| ROA | -41.6% | -62.8% | -56.3% | -10.5% | -17.8% |
| Net Profit Margin | -2,648.7% | - | -32,868.5% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
I-MAB SPONS.ADS/1 -0001 dividends
I-MAB SPONS.ADS/1 -0001 has not paid dividends in the last 5 fiscal years.
Who owns I-MAB SPONS.ADS/1 -0001
- Insiders 15.13%
- Institutions 34.20%
- Public & others 50.67%
- Shares outstanding 116M
- Free float 70.4M
I-MAB SPONS.ADS/1 -0001 company profile
- Company name
- I-MAB SPONS.ADS/1 -0001
- Ticker
- 0VY.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
- Fiscal year end
- December
- Address
- 2440 Research Boulevard, Rockville, MD, United States, 20850
- Phone
- 240 745 6330
- Website
- novabridge.com
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
I-MAB SPONS.ADS/1 -0001 management
2- Mr. Wei FuExecutive Chairman · born 1982
- Mr. Ming LeiChief Financial Officer · born 1997